Dicerna Pharmaceuticals reported $165.76M in Cash and Equivalent for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acceleron Pharma XLRN:US $ 336.46M 0.26M
Alnylam Pharmaceuticals ALNY:US $ 1093.99M 348.22M
Amgen AMGN:US $ 11969M 5339M
Arrowhead Research ARWR:US $ 184.43M 141.55M
Biogen BIIB:US $ 1541.8M 200.2M
Bluebird Bio BLUE:US $ 402.46M 48.99M
Dicerna Pharmaceuticals DRNA:US $ 165.76M 55.45M
Exelixis EXEL:US $ 567.33M 74.86M
Gilead Sciences GILD:US $ 6837M 1944M
GlaxoSmithKline GSK:LN 3453M 50M
Immunogen IMGN:US $ 245.76M 6.22M
Intercept Pharmaceuticals ICPT:US $ 428.77M 283.15M
Intrexon XON:US $ 41.73M 5.32M
IONIS PHARMACEUT IONS:US $ 1987M 1421.88M
Karyopharm Therapeutics KPTI:US $ 137.4M 3.91M
Lexicon Pharmaceuticals LXRX:US $ 120.92M 31.03M
Macrogenics MGNX:US $ 190.53M 1.56M
Mirati Therapeutics MRTX:US $ 176.78M 82.21M
Regeneron Pharmaceuticals REGN:US $ 3432.4M 1360.2M
Ultragenyx Pharmaceutical RARE:US $ 197.54M 93.34M